For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Testing The Addition Of An Anti-Cancer Immune Therapy Drug (Nivolumab) To The Usual Chemo Therapy Treatment (Cisplatin Or Carboplatin With Gemcitabine) For Recurrent Or Metastatic Nasopharyngeal Cancer
To compare the usual chemotherapy, cisplatin (or carboplatin) and gemcitabine alone to the usual chemotherapy plus an immune therapy drug, nivolumab.
DiagnosisPatient has nasopharyngeal carcinoma (NPC) that has recurred or spread outside of your nasopharynx.
Recurrent/Metastatic Nasopharnygeal carcinoma.
No prior systemic treatment for recurrent/metastatic disease.
No prior immunotherapy
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This study has two groups:
- Group 1: Patients will get the immune therapy study drug called nivolumab plus cisplatin (or carboplatin) and gemcitabine.
- Group 2: Patients will get Cisplatin (or carboplatin) and gemcitabine.
For more information, visit ClinicalTrials.gov